ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug. The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug. The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily. As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear." The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines. -By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
05/23/201616:40:00Samsung Targets U.S. Drug Market With Remicade Knockoff
05/20/201615:20:00Colombia Threatens to Override Novartis's Patent on Gleevec
05/20/201615:18:00Colombia Threatens to Override Novartis's Patent on Gleevec
05/18/201603:03:00Novartis Says Drug-Unit Chief To Leave Firm -- WSJ
05/17/201618:43:00ADRs End Lower; NQ Mobile Rises
05/17/201615:11:00Novartis to Split Pharmaceuticals Division into Two -- Update
05/17/201614:10:00Novartis to Split Drug Division
05/17/201613:27:00Novartis to Split Pharmaceuticals Division Into Two
05/05/201620:58:00Upsized IPO of Biotech Company Intellia Prices at Top of Range
05/03/201608:30:00Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer
05/03/201608:19:00Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer
04/29/201604:50:00AstraZeneca's Investment Eats Into Profit
04/28/201616:40:00Amgen Profit Rises 17%, Guidance Raised
04/27/201608:20:00GlaxoSmithKline Sees First-Quarter Profit Fall
04/26/201608:10:00Eli Lilly Revenue Boosted By New Drug Sales
04/22/201603:03:00Novartis Feels the Effect Of Drop in Gleevec Sales -- WSJ
04/21/201608:29:00Novartis Earnings Fall on Slide in Cancer-Drug Sales -- 2nd Update
04/21/201603:50:00Novartis Earnings Fall on Slide in Cancer-Drug Sales --Update
04/21/201602:10:00Novartis Earnings Fall on Slide in Cancer-Drug Sales
04/21/201602:03:00Novartis Earnings Fall on Slide in Cancer-Drug Sales

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad